Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax

ROCKVILLE, Md.--(BUSINESS WIRE)--Jan. 17, 2013-- Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 2 clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. NuThrax, a next generation vaccine being developed as part of Emergent's anthrax franchise, consists of Anthrax Vaccine Adsorbed in combination with a novel immunostimulatory adjuvant, CPG 7909. “Emergent is pleased to initiate this Phase 2 clinical trial of NuThrax, which supports the near-term goal and priority of the U.S. Department of Healt...